Board of Directors
Mr. Martin Gerstel, Chairman
Martin Gerstel is Chairman of Compugen Ltd., a publicly owned drug and diagnostic discovery company, of Keddem Bioscience, a privately owned drug discovery company and Co-Chairman of Itamar Medical, a publicly owned medical device company, all of which are headquartered in Israel. Prior to relocating to Israel in 1994, Mr. Gerstel was the Co-Chairman and CEO of ALZA Corporation, a pharmaceutical company based on advanced drug delivery.
In addition, Mr. Gerstel currently serves as a director of YEDA Technology Transfer, Yissum Technologies and the Foundation for the US National Medals of Science and Technology. He is a member of the Board of Governors and the Executive Committee of the Weizmann Institute of Science and the Board of Governors of the Hebrew University of Jerusalem, and is an advisor to the Burrill Life Science Funds and to the Board of the Israel-U.S. BiNational Industrial Research and Development (“BIRD”) Foundation.
Mr. Gerstel is a graduate of Yale University and the Stanford Graduate School of Business.
Mr. Ziv Kop
Ziv Kop is the Chief Operating Officer and member of the Board of Directors of Outbrain Inc. a web-based content discovery platform, as well as a director of Kamada Ltd (NASDAQ:KMDA).
Previously, and since its inception in 2003 until June 2013, Mr. Kop was a Managing Partner at GlenRock Israel, a private equity investment firm, where he managed a portfolio of growth companies in the fields of advanced technologies and healthcare, and served on the board of more than ten private and public companies.
Prior to his role at GlenRock, Mr. Kop served as Chief Executive Officer of POC Management Consulting, a leading Israeli consultancy in the field of strategic planning.
Mr. Kop holds an LLB and MBA from Tel Aviv University Law School and Business School, and is a graduate of INSEAD’s Young Managers Program.
Dr. Adina Makover
Dr. Adina Makover currently serves as Director of Life Sciences Investments at Proseed VC and is a consultant to private investors. For the past four years, Dr. Makover has been the managing director of Tzina Bio Perspective, a private investment company focusing on biotechnology and medical device ventures. Previously, she held senior management positions in biotech and device companies focusing on drugs, diagnostics and tissue engineering. Holding positions of CEO and board member, R&D, process development and production manager, Dr. Makover was responsible for both the technology and business aspects.
Dr. Makover holds a joint PhD degree in life sciences from Columbia University (USA) and Weizmann Institute of Science (Israel) and performed post-doctoral research at the Weizmann Institute of Science. Dr. Makover also holds an MBA degree from Bar-Ilan University.
Mr. Leon Recanati
Mr. Leon Recanati is the founder and CEO of GlenRock Israel, a private equity group. Mr. Recanati was Chairman and CEO of IDB Holding Corporation, one of the largest investment groups in Israel until May 2003. In addition, he served as Chairman of Clal Industries and Investments, Discount Investment Corporation, and Azorim Investment Development and Construction. Mr. Recanati was Chairman of Delek Israel Fuel Corporation and Super-Sol until 1997, in addition to several other positions in a variety of operating companies in Israel.
Mr. Recanati's personal involvement in organizations and diverse causes has earned him a reputation as one of Israel's outstanding community leaders. He is Chairman of the Board of the Israel National Museum of Science in Haifa, Vice Chairman of the Israel Cancer Association and Chairman of Tel-Aviv University's Development Committee. He is also an active member of the Board of Governors of Tel-Aviv University and the Hebrew University of Jerusalem, The Technion Israel Institute of Technology, The Jewish Agency, and Chairman of Tapuah - The Israeli Society for the Advancement of the Information Age.
Mr. Recanati received his BA and MBA degrees from The Hebrew University of Jerusalem and Honorary Doctorates from the Technion Israel Institute of Technology and Tel-Aviv University.
Dr. Kinneret Savitsky
Dr. Kinneret Savitsky serves as Chief Executive Officer at BioLineRx Ltd, a publicly traded biopharmaceutical development company. Previously, from 2004 to 2009, Dr. Savitsky served as the general manager of BioLine Innovations Jerusalem and was responsible for drug development acceleration and pre-clinical activities. Prior to joining BioLineRx, Dr. Savitsky served as the Vice President of Biology at Compugen Ltd. and was responsible for drug discovery and development in the company.
Dr. Savitsky holds a Ph.D. from the Tel Aviv University. Dr. Savitsky also holds a B.Sc. in Biology from the Hebrew University of Jerusalem and a Masters degree in Human Genetics from Tel Aviv University.
Ms. Sarit Firon
Ms. Sarit Firon serves as a managing partner of Cerca Partners, a venture capital investment fund, since 2016, where she previously served in the investment committee since 2014. In addition, Ms. Firon serves as chairperson of the board of directors of myThings, an ad-tech company, since 2015 and as a director in the following companies: DATORAMA, a marketing analytics company, since 2012; MediWound, a biotechnology company, since 2014; and Extreme Reality, a 3D motion capture gaming technology company, between 2014 – May 2016. Prior to that, Ms. Firon served as CEO of Extreme Reality from 2012 to 2014 and in several CFO positions since 1997 in Kenshoo, MediaMind, Olive Software, P-Cube, and RadCom.
Ms. Firon holds a B.A. in accounting and economics from Tel-Aviv University.